Erbitux (cetuximab) / Eli Lilly 
Welcome,         Profile    Billing    Logout  
 245 Diseases   389 Trials   389 Trials   11400 News 


«12...113114115116117118119120121122123...143144»
  • ||||||||||  telisotuzumab (h224G11) / AbbVie
    Trial completion, Enrollment change, Metastases:  Study of ABT-700 in Subjects With Advanced Solid Tumors (clinicaltrials.gov) -  Jun 7, 2017   
    P1,  N=74, Completed, 
    Trial primary completion date: May 2017 --> May 2019 Active, not recruiting --> Completed | N=124 --> 74
  • ||||||||||  EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
    Trial primary completion date, IO biomarker, Metastases:  Anti-CD3 x Anti-Erbitux (clinicaltrials.gov) -  May 31, 2017   
    P1,  N=30, Active, not recruiting, 
    Suspended --> Recruiting | N=120 --> 51 | Initiation date: Feb 2014 --> Aug 2016 | Trial primary completion date: Aug 2017 --> Nov 2017 Trial primary completion date: Jul 2016 --> Jan 2019
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck. (Pubmed Central) -  May 27, 2017   
    The major development of the past decade in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy (CT), followed by maintenance cetuximab (the "EXTREME" regimen)...Nivolumab and pembrolizumab are the first two ICIs that were approved by the US Food and Drug Administration...A number of ongoing clinical trials are comparing regimens with ICIs, alone and in combination with other ICIs or CT, with the EXTREME regimen for first-line treatment of R/M SCCHN. As we eagerly await the results of these trials, the EXTREME regimen remains the standard of care for the first-line treatment of R/M SCCHN.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, buparlisib (AN2025) / Novartis, Adlai Nortye
    Biomarker, Trial primary completion date, Combination therapy, Metastases:  PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer (clinicaltrials.gov) -  May 23, 2017   
    P1/2,  N=30, Active, not recruiting, 
    As we eagerly await the results of these trials, the EXTREME regimen remains the standard of care for the first-line treatment of R/M SCCHN. Trial primary completion date: Apr 2017 --> Apr 2018
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Enrollment closed, Trial primary completion date:  Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer (clinicaltrials.gov) -  May 22, 2017   
    P2,  N=63, Active, not recruiting, 
    Trial primary completion date: Apr 2017 --> Apr 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2015
  • ||||||||||  IMM-101 / Immodulon
    Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, Metastases:  Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer (clinicaltrials.gov) -  May 22, 2017   
    P1/2,  N=300, Recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2016 --> Nov 2015 Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017 | Trial primary completion date: Jan 2019 --> May 2019
  • ||||||||||  lapatinib / Generic mfg., Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Review, Journal:  ASCO Plenary Sessions: impact, legacy, future. (Pubmed Central) -  May 20, 2017   
    Who could have forseen bevacizumab displaced by several VEGF TKIs?  Third, negative trials are rare among Plenary sessions, but when they are presented they are immensely important.  Examples include a seminal study using CA-125 levels to guide treatment of relapsed ovarian cancer, the use of lapatinib combined with traztuzumab in the adjuvant treatment of HER2 + disease, and studies showing no survival benefit to upfront bevacizumab in glioblastoma multiforme.   Fourth, we note a large industry presence among Plenary sessions, as the Industry in part sponsored 62% of Plenary abstracts.  Ultimately a review of 9 years of ASCO plenary reveals the plenary for what it is: a conservative selection of abstracts that, at the time, are thought to change the face of oncology.  Time, however, is the true arbiter, and some succeed in this quest, while others falter.  ASCO plenary sessions reveal the influence, legacy and future of cancer care.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Biomarker, Trial completion:  Biomarkers in Patients With Head and Neck Cancer (clinicaltrials.gov) -  May 19, 2017   
    P=N/A,  N=70, Completed, 
    N=706 --> 987 Not yet recruiting --> Completed
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial primary completion date, Metastases:  Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck (clinicaltrials.gov) -  May 16, 2017   
    P2,  N=80, Active, not recruiting, 
    Not yet recruiting --> Completed Trial primary completion date: Apr 2017 --> Sep 2017
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Journal:  Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck. (Pubmed Central) -  May 12, 2017   
    This review summarizes the results of recently completed trials of anti-EGFR agents in SCCHN, highlights the various mechanisms that drive resistance to EGFR inhibitors in SCCHN, and focuses on several novel targeted agents that could potentially help overcome resistance to EGFR-based therapies in SCCHN. Expert commentary: Due to the development of resistance to EGFR-targeted therapies, novel treatment approaches to overcome resistance are a key unmet need for SCCHN.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Trial primary completion date, Combination therapy, Metastases:  Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination (clinicaltrials.gov) -  May 4, 2017   
    P1b,  N=44, Active, not recruiting, 
    The diagnostic and therapeutic convergence radiopharmaceutical (64)Cu-/(177)Lu-PCTA-cetuximab may be useful as a diagnostic tool in patient selection and a potent radioimmunotherapy agent in EGFR-positive ESCC tumors. Trial primary completion date: Jan 2017 --> Aug 2017
  • ||||||||||  patritumab (U3-1287) / Amgen, Daiichi Sankyo
    Trial primary completion date, Combination therapy, Metastases:  Patritumab With Cetuximab and a Platinum Agent for Squamous Cell Carcinoma (Cancer) of the Head and Neck (SCCHN ) (clinicaltrials.gov) -  May 1, 2017   
    P2,  N=105, Recruiting, 
    Although alcohol consumption was not associated with colon cancer outcomes overall, mild to moderate red wine consumption was suggestively associated with longer OS, DFS, and TTR in stage III colon cancer patients. Trial primary completion date: Apr 2017 --> Jul 2017
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Trial completion, Trial primary completion date:  Does Acne Rash During Adolescence Predict Skin Reaction to Cetuximab (clinicaltrials.gov) -  Apr 27, 2017   
    P=N/A,  N=100, Completed, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Apr 2017
  • ||||||||||  Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, LEAC-102 / Taiwan Bio
    Trial initiation date, Combination therapy, Metastases:  LEAC-102 for Advanced Colorectal Cancer (clinicaltrials.gov) -  Apr 26, 2017   
    P1/2,  N=30, Not yet recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: Mar 2016 --> Apr 2017 Initiation date: Feb 2017 --> Jun 2017